Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Circulating Metastases DNA Tracking for Ovarian Cancer Recurrence

admin by admin
November 30, 2022
in News


The most deadly gynecologic cancer is epithelial ovarian cancer (EOC). Before surgery and during follow-up after therapy, researchers investigated whether circulating tumor DNA (ctDNA) could be a useful predictive biomarker for early-stage ovarian cancer by comparing it to the patient outcome and CA-125. Plasma was taken from patients with EOC at stages I through IV. Patients in Cohort A had samples taken before surgery (N = 44, median follow-up: 2.7 years), while Cohorts B and C had samples taken serially after surgery (N = 12) and during surveillance (N = 13) (median follow-up: 2 years). 

A tumor-informed, tailored multiplex-PCR NGS assay was used to examine plasma samples, and the results showed that ctDNA status and CA-125 levels were both connected with clinical characteristics and outcomes. Every member of the their genome sequenced, and the results were in line with those found in TCGA. Cohort A had a greater rate of ctDNA-positivity in high nuclear grade illness, with 73% (32/44) of presurgical samples testing positive. Only relapsing patients’ ctDNA was found (100% sensitivity and specificity) in cohorts B and C, and it lagged behind radiological findings by an average of 10 months. 

When compared to CA-125 positive (P = 0.113 and P = 0.056), the presence of ctDNA at a single time point after surgery +/- adjuvant chemotherapy and serially during surveillance was a substantial predictor of relapse (HR:17.6, P = 0.001 and P < 0.0001, respectively). Postoperative ctDNA detection is strongly associated with poor prognosis in terms of time before cancer returns after surgery. When it came to predicting which patients will experience a recurrence, CtDNA fared better than CA-125. From these findings, it appears that ctDNA monitoring may aid in clinical decision making for individuals with EOC.

Source: sciencedirect.com/science/article/pii/S009082582200590X



Source link

Advertisement Banner
Previous Post

Which Suction Catheter Tip Do You Need?

Next Post

Barcodes Are Us – The Health Care Blog

Related Posts

News

Unvaccinated status increases risk of long COVID symptoms

January 29, 2023
News

Rezafungin is non-inferior to caspofungin in the treatment of candidemia and invasive candidiasis

January 28, 2023
News

An Analysis of HDL-bound Apolipoproteins in NAFLD Patients with Advanced Liver Fibrosis

January 27, 2023
News

Restrictive, Liberal Fluid Strategies Yield Similar Outcomes for Sepsis-Induced Hypotension

January 26, 2023
News

Mild to Moderate Cerebral Palsy in Young Children Treated with Vibration Therapy

January 25, 2023
News

Serrated Neoplasia Pathway to Colorectal Cancer Reveals Early Immune and Molecular Alterations

January 24, 2023
Next Post

Barcodes Are Us – The Health Care Blog

Recommended

Best Pillows for Stomach Sleepers of 2022

2 months ago

What is a CleanTech® EVO Automated Handwashing Station?

2 weeks ago

The Constitution, Health, and Culture in America – The Health Care Blog

1 month ago

The AMA v. Dobbs. Part 2. – The Health Care Blog

2 months ago

Medical Fiction: Kyle and the Mistake

3 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.